Back

CENTOGENE Signs MOU with Republic of Tajikistan

CENTOGENE AG announced that it has signed a Memorandum of Understanding (MOU) with the Ministry of Health & Social Protection of the Population, Republic of Tajikistan. The MOU collaboration framework is intended to stimulate and facilitate the wellbeing of patients with genetic diseases, advance international scientific research, and enhance medical education in Tajikistan on issues related to the diagnostics of rare diseases.

“We are honored to be collaborating with the Republic of Tajikistan in order to enable the early diagnosis of hereditary genetic diseases, support the education of rare disease diagnosis and treatment, and drive sustainable clinical research,” said Dr. Arndt Rolfs, CEO CENTOGENE. “Our priority with this collaboration is to help end the diagnostic odyssey that rare disease patients face in Tajikistan, and bring hope to patients with rare diseases and their families.”

The intended cooperation includes education, capacity development and clinical research related to hereditary genetic diseases, and the genetic diagnosis of patients in Tajikistan where a rare  hereditary disease is suspected. Further details of the cooperation will be finalized over the next few months.

Subscribe to our Newsletter

To receive the latest news and developments in clinical diagnostics and scientific breakthroughs in the rare disease field please click subscribe. After that, you will receive an email with a confirmation link. Once you have clicked on that link, we will inform you about our products, services and upcoming events per e-mail. You can unsubscribe from the newsletter with effect for the future at any time using the unsubscribe link contained in every newsletter.